Answers are grounded in this paper and cite their sources.
Treatment enhances T cell activity and reduces myeloid cells in brain tumors, suggesting improved outcomes with CAR T cells.
Advanced solid tumors pose significant clinical challenges due to a heterogeneous and immunosuppressive tumor microenvironment, which limits the efficacy of approved therapies. Based on promising clinical trial results with the oncolytic adenovirus (OA) Delta-24-RGD in glioma patients, we previously demonstrated that Delta-24-RGDOX, engineered to express the immune co-stimulatory molecule OX40 ligand (OX40L), enhances local and systemic anti-tumor immunity via an in situ autovaccination effect in immunocompetent mice bearing orthotopic intracranial (i.c.) gliomas or disseminated subcutaneous (s.c.)/i.c. melanomas. To further enhance therapeutic efficacy, we developed Delta-24-RGDOX-IL15, a novel OA co-expressing IL-15 and OX40L. IL-15 is known to activate NK and T cells and support the persistence of CD8⁺ memory T cells. Delta-24-RGDOX-IL15 maintained robust viral replication and oncolytic activity comparable to its predecessors and more effectively stimulated T cell responses, including CAR T cells, against cancer cells expressing corresponding tumor-associated antigen. In C57BL/6 mice bearing syngeneic GD2-expressing tumors, including i.c. gliomas or disseminated s.c./i.c. melanomas, intratumoral delivery of Delta-24-RGDOX-IL15 into the i.c. glioma or s.c. melanoma significantly reduced microglia and myeloid cell frequency while increasing T cell frequency and activation of NK, dendritic, and T cells within the tumor-bearing brain hemisphere from the mice of the two mouse models. Notably, when combined with murine GD2 CAR T cells, Delta-24-RGDOX-IL15 enhanced CAR T cell accumulation in both treated and distant, untreated brain tumors, leading to long-term survival in 20% of mice with s.c./i.c. melanomas. Currently, we are optimizing the treatment regimen to achieve better efficacy in both mouse models. Together, these findings demonstrate the potent immunostimulatory and therapeutic activity of Delta-24-RGDOX-IL15 and its potential to synergize with CAR T cell therapy in treating advanced primary or metastatic brain tumors.
No takes yet. Share an insight, caveat, or question.
Jiang et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: